UV1 peptide vaccine, which consists of three peptides [(peptide 725; TERT 691-705 (RTFVLRVRAQDPPPE), peptide 719-20; TERT 660-689 (ALFSVLNYERARRPGLLGASVLGLDDIHRA), peptide 728; TERT 651-665 (AERLTSRVKALFSVL)] and GM-CSF as adjuvant, has been used in combination with androgen deprivation therapy and radiotherapy to treat patients with androgene-sensitive metastatic prostate cancer in phase I/II trial (NCT01784913). This evidence concerns the gene TERT and metastatic prostate carcinoma.